Insmed (STU:IM8N) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IM8N Insmed Inc STU:IM8N
75 GF Score
Price €104.32
GF Value €190.41
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Insmed  (STU:IM8N) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Insmed Cyclically Adjusted PS Ratio Related Terms


Insmed Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Insmed's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insmed Cyclically Adjusted PS Ratio Chart

Insmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.07 15.49 18.80 40.37 81.95

Insmed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.21 62.57 74.22 65.85 40.57

STU:IM8N vs BNTX, INCY, ROIV: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Insmed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insmed Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Insmed's Cyclically Adjusted PS Ratio falls into.


STU:IM8N
75GF Score
Insmed Inc STU:IM8N
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insmed Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Insmed's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Insmed's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.684/333.9520*333.9520
=1.684

Current CPI (Jun. 2026) = 333.9520.

Insmed Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 0.000 246.524 0.000
201803 0.000 249.554 0.000
201806 0.000 251.989 0.000
201809 0.000 252.439 0.000
201812 0.112 251.233 0.149
201903 0.249 254.202 0.327
201906 0.326 256.143 0.425
201909 0.392 256.759 0.510
201912 0.461 256.974 0.599
202003 0.373 258.115 0.483
202006 0.399 257.797 0.517
202009 0.368 260.280 0.472
202012 0.340 260.474 0.436
202103 0.324 264.877 0.408
202106 0.344 271.696 0.423
202109 0.339 274.310 0.413
202112 0.414 278.802 0.496
202203 0.398 287.504 0.462
202206 0.512 296.311 0.577
202209 0.557 296.808 0.627
202212 0.438 296.797 0.493
202303 0.446 301.836 0.493
202306 0.516 305.109 0.565
202309 0.509 307.789 0.552
202312 0.538 306.746 0.586
202403 0.469 312.332 0.501
202406 0.542 314.175 0.576
202409 0.490 315.301 0.519
202412 0.547 315.605 0.579
202503 0.488 319.799 0.510
202506 0.501 322.561 0.519
202509 0.575 324.800 0.591
202512 1.061 324.054 1.093
202603 1.214 330.213 1.228
202606 1.684 333.952 1.684

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Insmed (STU:IM8N) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of €104.32 is trading 45.2% below its estimated GF Value™ of €190.41. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for STU:IM8N:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €190.41 vs. price of €104.32 (45.2% below fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the STU:IM8N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
75GF Score

Get the complete analysis for STU:IM8N

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€104.32
Price
€190.41
GF Value